Table 1.

Patient’s characteristics including sample type, BCR-ABL1/ABL1 ratio before/after imatinib therapy for responders (R) and non-responders (NR)

Patient identifier	Age (at time of sampling)	Sample type	Gender	Response	BCR-ABL1/ABL1 ratio (at time of sampling)	BCR-ABL1/ABL1 ratio (after 18 months)
01	62	PB	M	R	0.8	8·10−4
02	42	PB	M	R	0.7	4·10−4
03	63	PB	F	R	0.8	9·10−4
04	63	PB	M	R	0.8	7·10−4
05	45	PB	F	R	0.5	1·10−4
06	27	PB	M	R	0.8	7·10−5
07	54	PB	F	R	0.8	7·10−4
08	50	PB	M	R	0.4	6·10−4
09	47	PB	M	R	0.4	3·10−5
10	71	PB	M	R	0.5	2·10−5
11	57	PB	M	R	0.9	8·10−4
12	61	PB	F	R	0.7	4·10−4
Median BCR-ABL1/ABL1 ratio of PB responders					0.75	5·10−4
13	81	PB	F	NR	n.d	1·100
14	79	PB	M	NR	0.8	2·10−1
15	71	PB	M	NR	n.d	2·10−1
16	46	PB	M	NR	n.d	1.1·100
17	50	PB	M	NR	0.6	5·10−1
18	82	PB	F	NR	0.2	2·10−1
19	78	PB	F	NR	0.3	3·10−1
20	54	PB	F	NR	0.5	4·10−1
21	54	PB	M	NR	0.9	2·10−2
22	86	PB	F	NR	0.1	1·10−1
23	77	PB	F	NR	0.5	2·10−1
24	20	PB	M	NR	0.7	7·10−1
25	42	PB	M	NR	1.5	9·10−1
26	62	PB	F	NR	0.4	2·10−1
27	54	PB	M	NR	0.4	3·10−2
28	46	PB	M	NR	1.0	3·10−1
Median BCR-ABL1/ABL1 ratio of PB non-responders					0.5	2.5·10−1
29	30	BM	M	R	0.3	7·10−4
30	52	BM	M	R	1.1	1·10−3
31	71	BM	F	R	0.8	2·10−4
32	70	BM	F	R	0.7	7·10−5
33	41	BM	F	R	1.3	2·10−3
34	72	BM	M	R	1.0	3·10−4
35	56	BM	M	R	0.4	6·10−4
36	81	BM	M	R	1.0	1·10−4
37	38	BM	M	R	0.6	1·10−4
38	69	BM	M	R	1.1	3·10−4
39	49	BM	M	R	1.3	4·10−4
40	71	BM	M	R	2.1	5·10−4
41	67	BM	F	R	1.0	8·10−5
42	80	BM	M	R	0.7	2·10−4
Median BCR-ABL1/ABL1 ratio of BM responders					0.7	3.5·10−4
43	72	BM	F	NR	0.7	5·10−1
44	43	BM	F	NR	0.6	2·10−2
45	19	BM	M	NR	0.7	5·10−2
Median BCR-ABL1/ABL1 ratio of BM non-responders					0.7	5·10−2

BM bone marrow, PB peripheral blood, n.d. not determined at this specific timepoint